Marina Miller1, Jae Youn Cho1, Alexa Pham1, Paul J Friedman2, Joe Ramsdell1, David H Broide3. 1. Department of Medicine, University of California, San Diego, CA. 2. Department of Radiology, University of California, San Diego, CA. 3. Department of Medicine, University of California, San Diego, CA. Electronic address: dbroide@ucsd.edu.
Abstract
BACKGROUND: Tobacco smoking is a principal cause of COPD-emphysema (COPD-E). Whether discontinuing smoking for at least 4 years halts airway inflammation and progression of COPD-E in prior smokers is unknown. In this study we investigated whether discontinuing smoking for approximately 4 years in ex-smokers with GOLD (Global Initiative for Chronic Lung Disease) stage IIb (moderately severe) COPD-E stopped airway inflammation (ie, sputum biomarkers) and halted the progression of COPD-E on chest CT scan. METHODS: Ten ex-smokers with COPD-E who had quit smoking underwent chest CT scans to document the extent of COPD-E, assessment of lung function (FEV(1) and diffusing capacity of lung for carbon monoxide), sputum induction for biomarkers of inflammation (measured by enzyme-linked immunosorbent assay), and blood cotinine levels at baseline and approximately 4 years later. Normal healthy subjects (n = 7) and normal current smokers with no CT scan evidence of COPD-E (n = 8) served as sputum biomarker comparison groups. RESULTS: After approximately 4 years of not smoking (documented by cotinine levels), ex-smokers with COPD-E had persistent increased levels of mediators of inflammation in sputum (myeloperoxidase, leukotriene B4, IL-8, monocyte chemoattractant protein-1, matrix metalloprotease-9), which was associated with significant progression of COPD-E on chest CT scan. CONCLUSIONS: Cessation of tobacco smoking in heavy smokers with moderately severe COPD-E is associated with evidence of persistent airway inflammation and progression of COPD-E on CT scan 4 years later. Discontinuing smoking may slow the rate of progression of moderate severity COPD-E, but it does not prevent persistent airway inflammation and significant progression of COPD-E on CT scan.
BACKGROUND:Tobacco smoking is a principal cause of COPD-emphysema (COPD-E). Whether discontinuing smoking for at least 4 years halts airway inflammation and progression of COPD-E in prior smokers is unknown. In this study we investigated whether discontinuing smoking for approximately 4 years in ex-smokers with GOLD (Global Initiative for Chronic Lung Disease) stage IIb (moderately severe) COPD-E stopped airway inflammation (ie, sputum biomarkers) and halted the progression of COPD-E on chest CT scan. METHODS: Ten ex-smokers with COPD-E who had quit smoking underwent chest CT scans to document the extent of COPD-E, assessment of lung function (FEV(1) and diffusing capacity of lung for carbon monoxide), sputum induction for biomarkers of inflammation (measured by enzyme-linked immunosorbent assay), and blood cotinine levels at baseline and approximately 4 years later. Normal healthy subjects (n = 7) and normal current smokers with no CT scan evidence of COPD-E (n = 8) served as sputum biomarker comparison groups. RESULTS: After approximately 4 years of not smoking (documented by cotinine levels), ex-smokers with COPD-E had persistent increased levels of mediators of inflammation in sputum (myeloperoxidase, leukotriene B4, IL-8, monocyte chemoattractant protein-1, matrix metalloprotease-9), which was associated with significant progression of COPD-E on chest CT scan. CONCLUSIONS: Cessation of tobacco smoking in heavy smokers with moderately severe COPD-E is associated with evidence of persistent airway inflammation and progression of COPD-E on CT scan 4 years later. Discontinuing smoking may slow the rate of progression of moderate severity COPD-E, but it does not prevent persistent airway inflammation and significant progression of COPD-E on CT scan.
Authors: K Soejima; K Yamaguchi; E Kohda; K Takeshita; Y Ito; H Mastubara; T Oguma; T Inoue; Y Okubo; K Amakawa; H Tateno; T Shiomi Journal: Am J Respir Crit Care Med Date: 2000-04 Impact factor: 21.405
Authors: B W M Willemse; N H T ten Hacken; B Rutgers; I G A T Lesman-Leegte; W Timens; D S Postma Journal: Eur Respir J Date: 2004-09 Impact factor: 16.671
Authors: A Ekberg-Jansson; B Andersson; B Bake; M Boijsen; I Enanden; A Rosengren; B E Skoogh; U Tylén; P Venge; C G Löfdahl Journal: Respir Med Date: 2001-05 Impact factor: 3.415
Authors: Jeanine M D'Armiento; Steven M Scharf; Michael D Roth; John E Connett; Andrew Ghio; David Sternberg; Jonathan G Goldin; Thomas A Louis; Jenny T Mao; George T O'Connor; Joe W Ramsdell; Andrew L Ries; Neil W Schluger; Frank C Sciurba; Melissa A Skeans; Helen Voelker; Robert E Walter; Christine H Wendt; Gail G Weinmann; Robert A Wise; Robert F Foronjy Journal: Respir Res Date: 2009-11-19
Authors: J Michael Wells; Patricia L Jackson; Liliana Viera; Surya P Bhatt; Joshua Gautney; Guy Handley; R Wilson King; Xin Xu; Amit Gaggar; William C Bailey; Mark T Dransfield; J Edwin Blalock Journal: Am J Respir Crit Care Med Date: 2015-10-15 Impact factor: 21.405
Authors: Krzysztof Kamocki; Mary Van Demark; Amanda Fisher; Natalia I Rush; Robert G Presson; Walter Hubbard; Evgeny V Berdyshev; Swetlana Adamsky; Elena Feinstein; Aneta Gandjeva; Rubin M Tuder; Irina Petrache Journal: Am J Respir Cell Mol Biol Date: 2012-09-28 Impact factor: 6.914
Authors: Wei Rao; Shan Wang; Marcin Duleba; Suchan Niroula; Kristina Goller; Jingzhong Xie; Rajasekaran Mahalingam; Rahul Neupane; Audrey-Ann Liew; Matthew Vincent; Kenichi Okuda; Wanda K O'Neal; Richard C Boucher; Burton F Dickey; Michael E Wechsler; Omar Ibrahim; John F Engelhardt; Tinne C J Mertens; Wei Wang; Soma S K Jyothula; Christopher P Crum; Harry Karmouty-Quintana; Kalpaj R Parekh; Mark L Metersky; Frank D McKeon; Wa Xian Journal: Cell Date: 2020-04-15 Impact factor: 41.582
Authors: Saskia A Overbeek; Saskia Braber; Pim J Koelink; Paul A J Henricks; Esmaeil Mortaz; Adele T LoTam Loi; Patricia L Jackson; Johan Garssen; Gerry T M Wagenaar; Wim Timens; Leo Koenderman; J Edwin Blalock; Aletta D Kraneveld; Gert Folkerts Journal: PLoS One Date: 2013-01-31 Impact factor: 3.240